Literature DB >> 1912015

Treatment of Pseudomonas infections in peritoneal dialysis patients.

T E Taber1, T F Hegeman, S M York, R A Kinney, D H Webb.   

Abstract

Pseudomonas species infections in the peritoneal dialysis population consist primarily of peritonitis or exit site infections. These organisms have traditionally proven difficult to eradicate, and the standard antibiotic regimen has carried the potential for nephrotoxicity. At our institution, all peritoneal dialysis patients with Pseudomonas exit site infections or peritonitis were treated with an antibiotic combination of intraperitoneal ceftazidime and oral ciprofloxacin. Treatment duration was dependent upon the site of infection. Recurrent exit site infections were treated with a repeated course of the antibiotics, and with surgical debridement and subsequent shaving of the external cuff of double-cuffed catheters. We saw a total of 11 Pseudomonas aeruginosa exit site infections in 7 patients (4 recurrent). Patients with recurrent infections were subsequently cured with the regimen as outlined above. Of 7 patients with Pseudomonas species peritonitis (aeruginosa, fluorescens, stutszeri, and maltophilia), 5 were cured with the initial antibiotic regimen. The 2 failures were both infected with Pseudomonas maltophilia, which is consistent with observed organism sensitivity data. The combination of ceftazidime and ciprofloxacin with the option for surgical debridement of the external cuff (in exit site infections) appears effective in the treatment of Pseudomonas species infections in the peritoneal dialysis population. Sensitivity data should be used to adjust the antibiotic regimen when appropriate.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1912015

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  8 in total

1.  Type III secretion system and virulence markers highlight similarities and differences between human- and plant-associated pseudomonads related to Pseudomonas fluorescens and P. putida.

Authors:  Sylvie Mazurier; Annabelle Merieau; Dorian Bergeau; Victorien Decoin; Daniel Sperandio; Alexandre Crépin; Corinne Barbey; Katy Jeannot; Maïté Vicré-Gibouin; Patrick Plésiat; Philippe Lemanceau; Xavier Latour
Journal:  Appl Environ Microbiol       Date:  2015-01-30       Impact factor: 4.792

2.  Spontaneous Bacterial Peritonitis by Burkholderia cepacia Complex: A Rare, Difficult to Treat Infection in Decompensated Cirrhotic Patients.

Authors:  Sunil Taneja; Pramod Kumar; Vikas Gautam; Ajay Duseja; Virendra Singh; Radha K Dhiman; Yogesh Chawla
Journal:  J Clin Exp Hepatol       Date:  2016-08-28

3.  Spread of Pseudomonas fluorescens due to contaminated drinking water in a bone marrow transplant unit.

Authors:  Vanessa Wong; Katrina Levi; Buket Baddal; Jane Turton; Tim C Boswell
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

Review 4.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  Atg7 Deficiency Intensifies Inflammasome Activation and Pyroptosis in Pseudomonas Sepsis.

Authors:  Qinqin Pu; Changpei Gan; Rongpeng Li; Yi Li; Shirui Tan; Xuefeng Li; Yuquan Wei; Lefu Lan; Xin Deng; Haihua Liang; Feng Ma; Min Wu
Journal:  J Immunol       Date:  2017-03-03       Impact factor: 5.422

Review 6.  Peritoneal dialysis. Prevention and control of infection.

Authors:  R Gokal
Journal:  Drugs Aging       Date:  2000-10       Impact factor: 3.923

7.  Two novel clinical presentations of Burkholderia cepacia infection.

Authors:  Chiranjoy Mukhopadhyay; Anudita Bhargava; Archana Ayyagari
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

8.  Stenotrophomonas maltophilia infection in patients receiving continuous ambulatory peritoneal dialysis.

Authors:  Joo-Eun Baek; Eun-Young Jung; Hyun-Jung Kim; Gyeong-Won Lee; Jong-Ryeal Hahm; Kee-Ryeon Kang; Se-Ho Chang
Journal:  Korean J Intern Med       Date:  2004-06       Impact factor: 2.884

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.